Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.

Anne Christine Bay-JensenAdam PlattMartin A JenkinsMichael E WeinblattInger ByrjalsenKishwar MusaMark C GenoveseMorten A Karsdal

Published in: BMC rheumatology (2019)

Serum C1M and CRP showed prognostic value and may be tools for enrichment of clinical trials with structural progressor. The two markers reflect two different aspect of disease pathogenesis (tissue turnover vs. inflammation), thus may provide individual and supplementary information.

Keyphrases

rheumatoid arthritis
clinical trial
oxidative stress
bone mineral density
healthcare
randomized controlled trial
health information
body composition
study protocol
tissue engineering
open label